Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger

Neurocrine Biosciences' acquisition of Soleno Therapeutics marks a significant step in advancing treatments for rare diseases, particularly those causing severe symptoms like relentless hunger. This deal highlights the growing focus on specialized therapies within the biotech industry, offering hope for patients with unmet medical needs. For consumers, it signals potential new treatment options and increased innovation in managing rare conditions.

• The $2.9 billion acquisition aims to expand Neurocrine's portfolio in endocrinology and rare diseases.
• Focus on developing therapies for conditions with limited existing treatment options.
• Reflects a broader industry trend toward mergers and acquisitions to accelerate drug development.